J Cancer 2017; 8(14):2846-2853. doi:10.7150/jca.19897
ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy
1. Medical school of Southeast University, Nanjing 210009, China;
2. Department of Respiratory Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, China;
3. Center of Clinical Laboratory Medicine, Zhongda Hospital, Southeast University, Nanjing, 210009, China.
Wang X, Zhu X, Zhang H, Fan X, Xue X, Chen Y, Ding C, Zhao J, Wu G. ERCC1_202 Is A Prognostic Biomarker in Advanced Stage Non-Small Cell Lung Cancer Patients Treated with Platinum-Based Chemotherapy. J Cancer 2017; 8(14):2846-2853. doi:10.7150/jca.19897. Available from http://www.jcancer.org/v08p2846.htm
Purpose: To develop a qPCR method to examine the 202 isoform of excision repair cross-complementation group 1 (ERCC1_202) and to evaluate its clinical utility as a predictive biomarker for platinum-based chemotherapy in non-small cell lung cancer (NSCLC).
Methods: The relative complementary DNA (cDNA) quantification for ERCC1_202 was conducted using a fluorescence-based, real-time detection method and β-actin was used as a reference gene.
Results: A strong correlation was observed between ERCC1_202 mRNA and ERCC1 mRNA levels in NSCLC cells (P < 0.001). 28 patients completed this research. Our results implied that as ERCC1_202 levels increased, the risk of progression (HR = 4.296, P = 0.011) and death (HR = 6.503, P = 0.001) increased. At multivariate analysis, high expression of ERCC1_202 was shown to be an independent predictive factor for time to progression (P = 0.047), and progression-free survival (P = 0.014). However, the high expression of ERCC1_202 was not an independent predictive factor for response (P = 0.324).
Conclusions: This study suggests that the efficacy of platinum-based chemotherapy can be improved when customized according to the expression of ERCC1_202.
Keywords: non-small cell lung cancer, ERCC-1, 202 isoform, Cisplatin, resistance.